Free Trial

Arvinas (ARVN) Stock Price, News & Analysis

Arvinas logo
$7.15 -0.35 (-4.64%)
As of 10:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Arvinas Stock (NASDAQ:ARVN)

Key Stats

Today's Range
$7.10
$7.50
50-Day Range
$6.07
$9.62
52-Week Range
$5.90
$34.34
Volume
246,178 shs
Average Volume
1.36 million shs
Market Capitalization
$522.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.92
Consensus Rating
Moderate Buy

Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

ARVN MarketRank™: 

Arvinas scored higher than 73% of companies evaluated by MarketBeat, and ranked 294th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 12 buy ratings, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arvinas has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arvinas' stock forecast and price target.
  • Earnings Growth

    Earnings for Arvinas are expected to grow in the coming year, from ($3.81) to ($3.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arvinas is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arvinas is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arvinas has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Arvinas' valuation and earnings.
  • Percentage of Shares Shorted

    12.63% of the float of Arvinas has been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently increased by 11.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arvinas does not currently pay a dividend.

  • Dividend Growth

    Arvinas does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.63% of the float of Arvinas has been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently increased by 11.22%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Arvinas has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Arvinas this week, compared to 6 articles on an average week.
  • Search Interest

    13 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,372.00 in company stock.

  • Percentage Held by Insiders

    Only 4.73% of the stock of Arvinas is held by insiders.

  • Percentage Held by Institutions

    95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arvinas' insider trading history.
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
Arvinas Inc.
See More Headlines

ARVN Stock Analysis - Frequently Asked Questions

Arvinas' stock was trading at $19.17 at the beginning of 2025. Since then, ARVN stock has decreased by 62.7% and is now trading at $7.1520.
View the best growth stocks for 2025 here
.

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings results on Thursday, May, 1st. The company reported $1.14 EPS for the quarter, topping the consensus estimate of ($0.93) by $2.07. The firm's quarterly revenue was up 646.2% compared to the same quarter last year.
Read the conference call transcript
.

Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Top institutional shareholders of Arvinas include Vanguard Group Inc. (11.46%), Alyeska Investment Group L.P. (2.47%), Millennium Management LLC (1.80%) and Philosophy Capital Management LLC (1.36%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Noah Berkowitz, Ronald Peck and David K Loomis.
View institutional ownership trends
.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/01/2025
Today
5/30/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
420
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.92
High Stock Price Target
$55.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+178.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
20 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$198.90 million
Pretax Margin
-75.29%

Debt

Sales & Book Value

Annual Sales
$426.90 million
Price / Cash Flow
N/A
Book Value
$8.17 per share
Price / Book
0.92

Miscellaneous

Free Float
65,175,000
Market Cap
$547.43 million
Optionable
Optionable
Beta
2.21
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ARVN) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners